KALA BIO, Inc. SEC filings document the company's common stock, capital structure, governance, material agreements, listing status, and strategic transition from a clinical-stage biopharmaceutical issuer toward a dual biotech and AI infrastructure model. Recent Form 8-K disclosures cover the 1-for-50 reverse stock split, amendments to the certificate of incorporation, Nasdaq minimum-bid-price matters, and executive and board changes.
The filings also record material contracts and financing arrangements, including the Researgency platform development and exclusive license agreement, shelf-registration activity, at-the-market offering documents, and registered direct offering disclosures. Periodic and notice filings address annual-report timing, operating and financial reporting, risk factors, and the documentation needed for the company's evolving biologics pipeline and AI platform strategy.
Kala Bio (NASDAQ:KALA) filed a routine Form 4 reporting that director Mark T. Iwicki sold 13,227 common shares on June 24 2025 at a weighted-average price of $4.01 per share, generating roughly $53 000 in gross proceeds.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 9 2020 to cover tax-withholding obligations related to the vesting of restricted stock units (RSUs) granted on June 22 2023.
After the sale, Iwicki retains 258 433 shares, including 103 540 unvested RSUs, meaning the disposition represents slightly under 5 % of his prior beneficial ownership. No changes to company operations, strategy, or financial condition are disclosed.
Form 144 Notice of Proposed Sale filed for Kala Bio (NASDAQ: KALA) indicates an insider's intent to sell 5,251 shares of common stock with an aggregate market value of $21,056.51 through E*TRADE Financial Corporation. The planned sale is scheduled for June 24, 2025.
The securities being sold were originally acquired through a Restricted Stock Unit (RSU) vesting on June 24, 2025, where the insider received 16,450 shares as equity compensation. The total shares outstanding for Kala Bio are reported at 6,452,398.
Recent trading activity by the same seller through E*TRADE includes a previous sale of 3,687 shares on June 3, 2025, which generated gross proceeds of $13,789.38. This Form 144 filing represents the seller's declaration that they are not aware of any material adverse non-public information regarding the company.
KALA BIO, Inc. has filed a Form 144 indicating a proposed sale of 3,631 shares of its common stock. The shares are to be sold through E*TRADE Financial on or after 24 June 2025 on the NASDAQ exchange. At the reference market price, the transaction is valued at approximately $14,560. The company reports 6,452,398 shares outstanding, so the contemplated sale represents roughly 0.06% of the float.
The shares were acquired via the vesting of Restricted Stock Units (RSUs) issued as equity compensation on the same date. During the past three months, the same account sold 2,850 shares on 3 June 2025 for gross proceeds of $10,659.
Rule 144 filings are routine administrative notices required before certain affiliate or insider sales. Given the small size relative to total shares and the absence of any disclosed adverse information, the filing appears immaterial to the company’s fundamentals and is unlikely to influence trading dynamics.